Patient equity and respiratory syncytial virus Immunoprophylaxis-Reference-Cited by-同舟云学术

Patient equity and respiratory syncytial virus Immunoprophylaxis

Published:2019-01-28 Issue:1 Volume:8 Page:
ISSN:2045-4015
Container-title:Israel Journal of Health Policy Research
language:en
Short-container-title:Isr J Health Policy Res

Author:

Cody Meissner H.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

http://link.springer.com/content/pdf/10.1186/s13584-019-0288-6.pdf

Reference23 articles.

1. Ginsberg GM, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis. Israel J Health Policy. 2018;7(1):63.

2. Hemp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of RSV prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165(6):498–505.

3. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3 pt 1):419–27.

4. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of RSV infection in infants. Cochrane Database Syst Rev 2013;30(4):CD006602.

5. ElHassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pedatr Adolesc Med. 2006;160:1070–6.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia;The Journal of Infection in Developing Countries;2021-11-30

2. Socioeconomic Impact of RSV Hospitalization;Infectious Diseases and Therapy;2021-03